Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Ampio Pharmaceuticals Inc. Stories

2013-06-07 08:24:48

GREENWOOD VILLAGE, Colo., June 7, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) has chosen to respond to a Seeking Alpha blog entry posted by Joe Dredly of Greenwich Research. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) The company wants to reassure the shareholder base that the transfer of our listing to the NYSE MKT is intended to help protect the shareholders' interests and the company has no plans to do an additional financing at this time....

2013-06-06 08:29:32

GREENWOOD VILLAGE, Colo., June 6, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it has received authorization from the NYSE Euronext (NYSE MKT) to transfer the listing from the NASDAQ Capital Market (NASDAQ). (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) The Company expects its common stock to begin trading on the NYSE MKT on Monday, June 17, under its current ticker symbol, AMPE, and it will celebrate the transfer of its listing by...

2013-06-03 08:28:09

GREENWOOD VILLAGE, Colo., June 3, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) today announced an update on its clinical progress for Ampion(TM), Optina(TM), the sexual dysfunction portfolio, and Luoxis Diagnostics, Inc. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Ampion In the SPRING trial, Ampion is being evaluated for its effect on reducing pain in osteoarthritis of the knee, measured by the WOMAC scale, as a single intra-articular injection into...

2013-05-13 08:28:41

GREENWOOD VILLAGE, Colo., May 13, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) today announced that it will present at the following conference: UBS Global Healthcare Conference, on Wednesday, May 22 2013 at 12:00 p.m. Eastern Time (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Ampio will webcast this management presentation, and the presentation may be accessed through the Company's website, www.ampiopharma.com, on the "Events and Presentations' page. An...

2013-04-25 08:34:34

GREENWOOD VILLAGE, Colo., April 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee. Twelve week primary endpoint data are expected in the third quarter of 2013. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) In the SPRING trial, Ampion is being evaluated for...

2013-04-02 04:21:16

GREENWOOD VILLAGE, Colo., April 2, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion(TM) to treat osteoarthritis (OA) of the knee. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer noted, "We are grateful to the FDA for suggesting our trial design include a run-in portion to assure...

2013-03-11 04:20:42

GREENWOOD VILLAGE, Colo., March 11, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE), a biopharmaceutical company developing drugs to treat prevalent inflammatory diseases, such as osteoarthritis (Ampion(TM)) and diabetic macular edema (Optina(TM)) and sexual dysfunction (Zertane(TM)) announced FDA acceptance of its POPE questionnaire, a modification of the Premature Ejaculation Profile (PEP) questionnaire that was used in the two successful Zertane(TM) Phase 3 clinical trials...

2013-02-27 04:22:07

GREENWOOD VILLAGE, Colo., Feb. 27, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema. The trial will evaluate Optina(TM) in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina(TM) 505(b)(2) status and drugs designated under this pathway can be approved on a single trial. (Logo:...

2013-02-25 04:22:14

GREENWOOD VILLAGE, Colo., Feb. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it's Phase III clinical study of Ampion(TM) for the treatment for osteoarthritis of the knee will include a dose-escalation run-in( )study as recommended by the FDA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained "In the Australian trial, a single 4 ml dose provided promising results...

2013-02-11 04:20:44

GREENWOOD VILLAGE, Colo., Feb. 11, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company focused on developing drugs to treat prevalent inflammatory diseases, such as osteoarthritis (OA) and diabetic macular edema (DME), announced the incorporation and initiation of operations of Luoxis Diagnostics, a subsidiary of Ampio that will initially be funded through a private placement, with Ampio maintaining approximately 80% ownership post financing. Josh...